ArticleAntimicrobial agents and chemotherapy2002
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Disposition of posaconazole following single-dose oral administration in healthy subjects.Antimicrobial agents and chemotherapy · 2004Trial
- Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.Antimicrobial agents and chemotherapy · 2004Trial
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.British journal of clinical pharmacology · 2004Trial
- Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.Antimicrobial agents and chemotherapy · 2003Trial
- Article
- Pulmonary Infiltrates in a Non-Cystic Fibrosis Bronchiectasis Patient: A Case Report.Journal of clinical medicine · 2025Article
- Clinical significance and antifungal susceptibility profile of 103 clinical isolates ofJournal of clinical microbiology · 2025Article
- A Case of Invasive Fungal Infection Due toInfection and drug resistance · 2023Article
- Non-European respiratory review : an official journal of the European Respiratory Society · 2022Article
- Review
- The synergistic effect of minocycline and azole antifungal drugs against Scedosporium and Lomentospora species.BMC microbiology · 2022Article
- Rapid Diagnosis of Central Nervous System Scedosporiosis by Specific Quantitative Polymerase Chain Reaction Applied to Formalin-Fixed, Paraffin-Embedded Tissue.Journal of fungi (Basel, Switzerland) · 2021Article
- Management of pulmonaryThe Journal of international medical research · 2020Article
- Therapeutic Challenges of Non-Antimicrobial agents and chemotherapy · 2019Review
- Utilization of voriconazole drug monitoring in the treatment of cutaneousMedical mycology case reports · 2018Article
- Effects of UVC Irradiation on Growth and Apoptosis ofInterdisciplinary perspectives on infectious diseases · 2018Article
- Fungal Diversity and Community Composition of Culturable Fungi inFrontiers in microbiology · 2018Article
- Article
- Rare fungal infectious agents: a lurking enemy.F1000Research · 2017Review
- Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection.Medical mycology case reports · 2016Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The susceptibilities of 13 clinical isolates of Scedosporium apiospermum and 55 clinical isolates of S. prolificans to new and conventional drugs belonging to three different classes of antifungal agents, the azoles (miconazole, itraconazole, voriconazole, UR-9825, posaconazole), the polyenes (amphotericin B, nystatin and liposomal nystatin), and allylamines (terbinafine), were studied by use of proposed standard M38-P of NCCLS. Low growth-inhibitory antifungal activities were found in vitro for most of the drugs tested against S. prolificans isolates, with the MICs at which 90% of isolates are inhibited (MIC(90)s) being >8 microg/ml; the MIC(90)s of voriconazole and UR-9825, however, were 4 microg/ml. S. apiospermum isolates were more susceptible in vitro, with the highest activity exhibited by voriconazole (MIC(90)s, 0.5 microg/ml), followed by miconazole (MIC(90)s, 1 microg/ml), UR-9825 and posaconazole (MIC(90)s, 2 microg/ml), and itraconazole (MIC(90)s, 4 microg/ml). The MICs of terbinafine, amphotericin B, and the two formulations of nystatin (for which no statistically significant differences in antifungal activities were found for the two species) for S. apiospermum isolates were high. Cross-resistance was observed among all the azoles except posaconazole and among all the polyenes except the lipid formulation. A distribution analysis was performed with the MICs of each drug and for each species. Bimodal and skewed MIC distributions were obtained, and cutoffs indicating the borders of different MIC subpopulations of the distributions were determined on the basis of the normal plot technique. These cutoffs were in many cases reproducible between 48 and 72 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.